NASDAQ OMX

Lumenis Unveils its new Moses™ Technology at European Association of Urology Annual Congress

22.3.2017 11:22 | NASDAQ OMX

Del

YOKNEAM, Israel, 2017-03-22 11:22 CET (GLOBE NEWSWIRE) -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announces the upcoming launch of its new Moses™ holmium technology in a range of launch events at the 32nd annual European Association of Urology (EAU) Congress, taking place in London from March 24-27, 2017.

Moses™ is a new breakthrough patent pending technology that redefines holmium lithotripsy technology as it exists today. The unique Moses technology is designed to significantly reduce retropulsion during lithotripsy, enabling less stone migration and a more efficient procedure. Moses™ technology includes a proprietary combination of holmium lasers and fibers that optimize holmium energy transmission allowing the surgeon more control regardless of the working distance between the fiber and the stone. The Moses™ tailored premium fiber range of 200, 365, and 550 D/F/L is designed for optimal energy transmission and durability. Additionally, the Moses™ 200 D/F/L fiber allows surgeons to treat stones in difficult to reach locations, and enables smooth initial fiber insertion through a fully deflected scope.

Moses™ initial clinical experience was conducted by Prof. Mostafa Elhilali of McGill University Health Center Department of Urology in Montreal, Canada, a leading global expert in the field of urology. As part of the EAU Annual Congress scientific program, Prof. Elhilali will present his findings onsite in a poster presentation and in a dedicated workshop hosted by Lumenis. The clinical experience confirms that Moses™’ unique capabilities provide surgeons with better control during holmium lithotripsy procedures, including stone dusting and stone fragmentation. The data obtained shows a significant reduction in stone retropulsion that may lead to a reduction in stone migration and more efficient lithotripsy procedures.

“My experience with the Moses™ technology shows that it is a true breakthrough in holmium laser lithotripsy, demonstrating enhanced accessibility and significant reduction in retropulsion,” said Prof. Elhilali. “I am keen to continue my clinical work and further explore the potential procedural efficiency of the Moses™ technology.”

“Lumenis is excited to introduce this next generation, breakthrough technology that will revolutionize the world of holmium laser lithotripsy,” said Tzipi Ozer-Armon, CEO of Lumenis. “The invention of Moses™ is a culmination of over 20 years of experience in holmium lasers and our corporate commitment to science and innovation. To date, we have proudly offered industry-leading solutions for patients affected by urinary stones worldwide and look forward to the opportunity to explore clinical outcomes at the next level.”

Moses™ is also being evaluated further by additional leading global experts including Dr. Andrew Symes, Consultant Urological Surgeon, Brighton & Sussex University Hospital NHS Trust, UK, who noted: “The Moses™ technology provides a greater sense of control due to minimized retropulsion. This is particularly valuable when dusting large stones in the kidney, but also when dealing with upper ureteric stones.”

During the EAU Annual Congress, Lumenis will offer a wide range of launch activities, enabling participants to get a first-hand experience of the new technology:

  • Moses™ Poster Presentation - Prof. Mostafa Elhilali (Canada)
    Evaluation of the new Moses™ Technology of holmium laser lithotripsy: Initial clinical experience.
    Saturday March 25th 2017, 14:15 – 15:45 (Room London, North Hall, Level 1)
  • Moses™ Launch Cocktail Reception
    Learn about the new technology from leading experts over a glass of prosecco and canapés
    Sunday March 26th 2017, 17:00 – 17:30 (Lumenis booth G34)
  • Lumenis Industry Workshop – “Revealing Moses™, Revolutionary New Holmium Technology” - Prof. M Elhilali (Canada), Mr. Mark Cynk (UK), Mr. Tim Larner (UK), 
    A thorough introduction of the new Moses™ Technology and its advantages in laser lithotripsy. Additional overview of advanced BPH techniques 
    Sunday March 26th 2017, 17:45-19:15 (Room 9, Capital Suite, Level 3)

In addition, Lumenis booth G34 will host a variety of booth talks and live surgeries:

Saturday, March 25th 2017

  • Mr. Mark Cynk – High Power for Enucleation (Booth G34, 13:00 – 13:30)
  • Mr. Tim Larner – Xpeeda™ Holmium Vaporization (Booth G34, 14:00 – 14:30)
  • Mr. Rick Popert – Live HoLEP Surgery – Part III– Guy’s Hospital – (eURO-Auditorium, 14:25 – 14:40)
  • Mr. Mark Cynk – High Power for Enucleation (Booth G34, 15:30 – 16:00)
  • Mr. Tim Larner – Pre-recorded Xpeeda Holmium Vaporization (eURO-Auditorium, 16:45 – 16:55)
  • Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 17:00 – 17:30)

Sunday, March 26th 2017

  • Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 11:00 – 11:30)
  • Dr. Oleg Burlaka – Russian Market HoLEP Presentation (Booth G34, 12:00 – 12:30)
  • Mr. Tim Larner – Xpeeda Vaporization (Booth G34, 15:00 – 15:30)

Monday, March 27th 2017

  • Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 11:00 – 11:30)
  • Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 13:00 – 13:30)

About Lumenis

www.lumenis.com
Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

         MEDIA CONTACT
         Cassandra Dump, Pascale Communications
         Cassy@pascalecommunications.com
         619.971.1887

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38Pressemelding

Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia.  Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts

Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00Pressemelding

Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressemelding

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressemelding

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressemelding

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressemelding

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom